Raymond James upgraded Guardant Health to Outperform from Market Perform with a $27 price target.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GH:
- Guardant launches Shield blood-based screening test for CRC in South Korea
- Guardant Health price target lowered to $64 from $74 at Craig-Hallum
- Guardant Health raises FY23 revenue view to $553M-$556M, consensus $549.06M
- Guardant Health reports Q3 adjusted EPS (67c), consensus (95c)
- Guardant Health management to meet with BTIG